Mary T. Austin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mary T. Austin has a total of 133 co-authors. Here are the top co-authors by number of shared publications:
Emma C. Hamilton
Department of Pediatric Surgery, McGovern Medical School, Houston, TX; Center for Surgical Trials and Evidence-Based Practice, McGovern Medical School, Houston, TX
6 shared publicationsKevin P. Lally
Department of Pediatric Surgery, McGovern Medical School at the University of Texas Health Science Center at Houston
6 shared publications- Emma C. Hamilton
Department of Pediatric Surgery, The McGovern Medical School at the University of Texas Health Science Center at Houston, 6431 Fannin Street, Suite 5.258, Houston, TX 77030, United States; Center for Surgical Trials and Evidence-Based Practice, McGovern Medical School at The University of Texas Health Science Center at Houston, Houston, TX, United States
5 shared publications Andrea Hayes-Jordan
Department of Pediatric Surgery, McGovern Medical School, Houston, TX; Division of Pediatrics, Children's Cancer Hospital at the University of Texas M.D. Anderson Cancer Center, Houston, TX; Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX
4 shared publicationsCharles C. Miller
Department of Cardiothoracic and Vascular Surgery, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, Texas
4 shared publications- KuoJen Tsao
Department of Pediatric Surgery, McGovern Medical School at UTHealth Houston and Children's Memorial Hermann Hospital, Houston, TX, USA; Center for Surgical Trials and Evidence-Based Practice (CSTEP), McGovern Medical School at UTHealth Houston, Houston, TX, USA
4 shared publications
Latest Publications
- Top Cited Papers
- 20 March 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (9) , 1157-1167
Evaluation and Surgical Management of Pediatric Cutaneous Melanoma and Atypical Spitz and Non-Spitz Melanocytic Tumors (Melanocytomas): A Report From Children's Oncology Group
PURPOSE: The purpose of this study was to develop recommendations for the diagnostic evaluation and surgical management of cutaneous melanoma (CM) and atypical Spitz tumors (AST) and non-Spitz melanocytic tumors (melanocytomas) in pediatric (age 0-10 years) and adolescent (age 11-18 years) patients. METHODS: A Children's Oncology Group–led panel with external, multidisciplinary CM specialists convened to develop recommendations on the basis of available data and expertise. RESULTS: Thirty-three experts from multiple specialties (cutaneous/medical/surgical oncology, dermatology, and dermatopathology) established recommendations with supporting data from 87 peer-reviewed publications. RECOMMENDATIONS: (1) Excisional biopsies with 1-3 mm margins should be performed when feasible for clinically suspicious melanocytic neoplasms. (2) Definitive surgical treatment for CM, including wide local excision and sentinel lymph node biopsy (SLNB), should follow National Comprehensive Cancer Network Guidelines in the absence of data from pediatric-specific surgery trials and/or cohort studies. (3) Accurate classification of ASTs as benign or malignant is more likely with immunohistochemistry and next-generation sequencing. (4) It may not be possible to classify some ASTs as likely/definitively benign or malignant after clinicopathologic and/or molecular correlation, and these Spitz tumors of uncertain malignant potential should be excised with 5 mm margins. (5) ASTs favored to be benign should be excised with 1- to 3-mm margins if transected on biopsy. (6) Re-excision is not necessary if the AST does not extend to the biopsy margin(s) when complete/excisional biopsy was performed. (7) SLNB should not be performed for Spitz tumors unless a diagnosis of CM is favored on clinicopathologic evaluation. (8) Non-Spitz melanocytomas have a presumed increased risk for progression to CM and should be excised with 1- to 3-mm margins if transected on biopsy. (9) Re-excision of non-Spitz melanocytomas is not necessary if the lesion is completely excised on biopsy.
- 20 March 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (9) , 1157-1167
Top Cited PapersEvaluation and Surgical Management of Pediatric Cutaneous Melanoma and Atypical Spitz and Non-Spitz Melanocytic Tumors (Melanocytomas): A Report From Children's Oncology Group
PURPOSE: The purpose of this study was to develop recommendations for the diagnostic evaluation and surgical management of cutaneous melanoma (CM) and atypical Spitz tumors (AST) and non-Spitz melanocytic tumors (melanocytomas) in pediatric (age 0-10 years) and adolescent (age 11-18 years) patients. METHODS: A Children's Oncology Group–led panel with external, multidisciplinary CM specialists convened to develop recommendations on the basis of available data and expertise. RESULTS: Thirty-three experts from multiple specialties (cutaneous/medical/surgical oncology, dermatology, and dermatopathology) established recommendations with supporting data from 87 peer-reviewed publications. RECOMMENDATIONS: (1) Excisional biopsies with 1-3 mm margins should be performed when feasible for clinically suspicious melanocytic neoplasms. (2) Definitive surgical treatment for CM, including wide local excision and sentinel lymph node biopsy (SLNB), should follow National Comprehensive Cancer Network Guidelines in the absence of data from pediatric-specific surgery trials and/or cohort studies. (3) Accurate classification of ASTs as benign or malignant is more likely with immunohistochemistry and next-generation sequencing. (4) It may not be possible to classify some ASTs as likely/definitively benign or malignant after clinicopathologic and/or molecular correlation, and these Spitz tumors of uncertain malignant potential should be excised with 5 mm margins. (5) ASTs favored to be benign should be excised with 1- to 3-mm margins if transected on biopsy. (6) Re-excision is not necessary if the AST does not extend to the biopsy margin(s) when complete/excisional biopsy was performed. (7) SLNB should not be performed for Spitz tumors unless a diagnosis of CM is favored on clinicopathologic evaluation. (8) Non-Spitz melanocytomas have a presumed increased risk for progression to CM and should be excised with 1- to 3-mm margins if transected on biopsy. (9) Re-excision of non-Spitz melanocytomas is not necessary if the lesion is completely excised on biopsy.
- 29 January 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 32 (4) , 2891-2892
ASO Visual Abstract: Surgical Margins and Oncologic Outcomes Following Wedge Resection of Pulmonary Metastases in Pediatric and Young Adult Sarcoma Patients
- 29 January 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 32 (4) , 2891-2892
ASO Visual Abstract: Surgical Margins and Oncologic Outcomes Following Wedge Resection of Pulmonary Metastases in Pediatric and Young Adult Sarcoma Patients
- Open Access
- 17 January 2025
- Published by Oxford University Press (OUP) in Journal of Sickle Cell Disease
- Vol. 2 (1)
Challenging case of hemolytic anemia and splenic sequestration in sickle cell disease
A 5-year-old female with sickle cell disease (SCD) (Hb SS) and poor compliance with hydroxyurea (HU) presented with a decline in hemoglobin (Hb), splenomegaly, and vaso-occlusive crisis. All of which become overlapping clinical features of different complications of SCD, including delayed hemolytic transfusion reaction (DHTR), and warm autoimmune hemolytic anemia (wAIHA). This patient’s initial presentation was with an orbital bone infarct for which she received an Rh/Kell antigens-unmatched transfusion. Because of subsequent alloimmunization with anti-D, anti-C, anti-E, and nonspecific IgG antibodies, she was started on a chronic transfusion regimen. At follow-up, she was noted to have splenomegaly and critically low Hb levels. She was then found to have developed wAIHA, splenic sequestration, and hyperhemolysis syndrome/possible DHTR. Through multidisciplinary decision-making, she was treated with intravenous immunoglobulin, methylprednisolone, and rituximab to stabilize her Hb and manage splenic sequestration to then allow for fully phenotypically matched red blood cells’ transfusion. Her last Hb during the admission was 7.8 g/dL. At this point, splenectomy was done in a safer context as definitive treatment for recurrent sequestration and immune hemolysis. This case highlights several important aspects of the care of patients with SCD, including multiple complications, treatment, and the importance of multidisciplinary coordination in high-risk or complex cases.
- 17 January 2025
- Published by Oxford University Press (OUP) in Journal of Sickle Cell Disease
- Vol. 2 (1)
Open AccessChallenging case of hemolytic anemia and splenic sequestration in sickle cell disease
A 5-year-old female with sickle cell disease (SCD) (Hb SS) and poor compliance with hydroxyurea (HU) presented with a decline in hemoglobin (Hb), splenomegaly, and vaso-occlusive crisis. All of which become overlapping clinical features of different complications of SCD, including delayed hemolytic transfusion reaction (DHTR), and warm autoimmune hemolytic anemia (wAIHA). This patient’s initial presentation was with an orbital bone infarct for which she received an Rh/Kell antigens-unmatched transfusion. Because of subsequent alloimmunization with anti-D, anti-C, anti-E, and nonspecific IgG antibodies, she was started on a chronic transfusion regimen. At follow-up, she was noted to have splenomegaly and critically low Hb levels. She was then found to have developed wAIHA, splenic sequestration, and hyperhemolysis syndrome/possible DHTR. Through multidisciplinary decision-making, she was treated with intravenous immunoglobulin, methylprednisolone, and rituximab to stabilize her Hb and manage splenic sequestration to then allow for fully phenotypically matched red blood cells’ transfusion. Her last Hb during the admission was 7.8 g/dL. At this point, splenectomy was done in a safer context as definitive treatment for recurrent sequestration and immune hemolysis. This case highlights several important aspects of the care of patients with SCD, including multiple complications, treatment, and the importance of multidisciplinary coordination in high-risk or complex cases.
- Open Access
Development of an Enhanced Recovery Program in Pediatric, Adolescent, and Young Adult Surgical Oncology Patients
Enhanced recovery after surgery (ERAS) protocols are standardized perioperative treatment plans aimed at improving recovery time in patients following surgery using a multidisciplinary team approach. These protocols have been shown to optimize pain control, improve mobility, and decrease postoperative ileus and other surgical complications, thereby leading to a reduction in length of stay and readmission rates. To date, no ERAS-based protocols have been developed specifically for pediatric patients undergoing oncologic surgery. Our objective is to describe the development of a novel protocol for pediatric, adolescent, and young adult surgical oncology patients. Our protocol includes the following components: preoperative counseling, optimization of nutrition status, minimization of opioids, meticulous titration of fluids, and early mobilization. We describe the planning and implementation challenges and the successes of our protocol. The effectiveness of our program in improving perioperative outcomes in this surgical population could lead to the adaptation of such protocols for similar populations at other centers and would lend support to the use of ERAS in the pediatric population overall.
Open AccessDevelopment of an Enhanced Recovery Program in Pediatric, Adolescent, and Young Adult Surgical Oncology Patients
Enhanced recovery after surgery (ERAS) protocols are standardized perioperative treatment plans aimed at improving recovery time in patients following surgery using a multidisciplinary team approach. These protocols have been shown to optimize pain control, improve mobility, and decrease postoperative ileus and other surgical complications, thereby leading to a reduction in length of stay and readmission rates. To date, no ERAS-based protocols have been developed specifically for pediatric patients undergoing oncologic surgery. Our objective is to describe the development of a novel protocol for pediatric, adolescent, and young adult surgical oncology patients. Our protocol includes the following components: preoperative counseling, optimization of nutrition status, minimization of opioids, meticulous titration of fluids, and early mobilization. We describe the planning and implementation challenges and the successes of our protocol. The effectiveness of our program in improving perioperative outcomes in this surgical population could lead to the adaptation of such protocols for similar populations at other centers and would lend support to the use of ERAS in the pediatric population overall.
- 1 September 2020
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 55 (9) , 1714-1721
What’s new in pediatric melanoma: An update from the APSA cancer committee
- 1 September 2020
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 55 (9) , 1714-1721
What’s new in pediatric melanoma: An update from the APSA cancer committee
- 1 August 2018
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 53 (8) , 1478-1493
The digital divide in adoption and use of mobile health technology among caregivers of pediatric surgery patients
- 1 August 2018
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 53 (8) , 1478-1493
The digital divide in adoption and use of mobile health technology among caregivers of pediatric surgery patients
- 1 August 2018
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 53 (8) , 1621-1626
The impact of racial/ethnic disparities on survival for children and young adults with chest wall sarcoma: A population-based study
- 1 August 2018
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 53 (8) , 1621-1626
The impact of racial/ethnic disparities on survival for children and young adults with chest wall sarcoma: A population-based study
- 1 April 2018
- Published by Elsevier in Journal of Surgical Research
- Vol. 224, 44-49
Retroperitoneal lymph node staging in paratesticular rhabdomyosarcoma—are we meeting expectations?
- 1 April 2018
- Published by Elsevier in Journal of Surgical Research
- Vol. 224, 44-49
Retroperitoneal lymph node staging in paratesticular rhabdomyosarcoma—are we meeting expectations?
- 1 January 2018
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 53 (1) , 163-168
Liver transplantation for primary hepatic malignancies of childhood: The UNOS experience
- 1 January 2018
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 53 (1) , 163-168
Liver transplantation for primary hepatic malignancies of childhood: The UNOS experience
- 1 January 2018
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 53 (1) , 169-173
The impact of racial/ethnic disparities on survival for children and adolescents with extremity sarcomas: A population-based study
- 1 January 2018
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 53 (1) , 169-173
The impact of racial/ethnic disparities on survival for children and adolescents with extremity sarcomas: A population-based study